Last reviewed · How we verify
cyclophosphamide, fludarabine, and antithymocyte globulin
cyclophosphamide, fludarabine, and antithymocyte globulin is a Small molecule drug developed by Asan Medical Center. It is currently in Phase 2 development.
At a glance
| Generic name | cyclophosphamide, fludarabine, and antithymocyte globulin |
|---|---|
| Sponsor | Asan Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (PHASE1)
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
- Stem Cell Transplantation in Crohn's Disease (PHASE1, PHASE2)
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) (PHASE3)
- Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia (PHASE2)
- Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cyclophosphamide, fludarabine, and antithymocyte globulin CI brief — competitive landscape report
- cyclophosphamide, fludarabine, and antithymocyte globulin updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about cyclophosphamide, fludarabine, and antithymocyte globulin
What is cyclophosphamide, fludarabine, and antithymocyte globulin?
cyclophosphamide, fludarabine, and antithymocyte globulin is a Small molecule drug developed by Asan Medical Center.
Who makes cyclophosphamide, fludarabine, and antithymocyte globulin?
cyclophosphamide, fludarabine, and antithymocyte globulin is developed by Asan Medical Center (see full Asan Medical Center pipeline at /company/asan-medical-center).
What development phase is cyclophosphamide, fludarabine, and antithymocyte globulin in?
cyclophosphamide, fludarabine, and antithymocyte globulin is in Phase 2.